Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bromoform is a brominated organic compound with the chemical formula CHBr3. It is a colorless to yellow liquid at room temperature with a sweet odor similar to chloroform and has a high density. Bromoform belongs to the class of haloforms and is also known as tribromomethane. Historically, it was used as a solvent, sedative (notably for children with whooping cough), fire retardant, and in mineral separation due to its high density. Currently, its primary use is as a laboratory reagent and in geological or electronics testing[5][6]. Bromoform acts as an **inhibitor** of the **methanogenesis pathway** in ruminants by interfering with microbial methane production pathways; this property has led to research into its use as an additive in livestock feed (notably via seaweed containing bromoform) for reducing methane emissions[5]. Bromoform exhibits central nervous system depressant effects at high exposures and can cause sedation or unconsciousness; chronic exposure may lead to liver or kidney injury[3][4]. It is classified by the EPA as a probable human carcinogen[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bromoform.